AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02346773 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product was a similar margarine with the same sensory properties, but with monounsaturated fatty acids (MUFA; refined plant oils) replacing EPA and DHA; total saturated fatty acids (SAFA) and ω-6 long chain polyunsaturated fatty acids (LC-PUFA) content were similar between the active and placebo products.
Study NCT02184455 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DermGEN
Description: DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
Study NCT02718170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buried Intramedullary K-wire Fixation
Study NCT02718170 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plate and Screw Fixation
Study NCT04518995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543 matching placebo
Description: Administered as tablets.
Study NCT04518995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Administered as tablets.
Study NCT04518995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CTP-543
Description: Administered as tablets.
Study NCT03610100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acelarin
Description: 825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
Study NCT03610100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
Study NCT00717704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: by vein once every 3 weeks
Study NCT00717704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: by mouth once daily
Study NCT03872076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The Drom Jump technique with the legs flexed will be performed with the patient standing in front of a bench 30 cm high by 100 cm wide. The physiotherapist will be placed lateral to the athlete. The subject will be asked to jump up from the box or bench, with the hip and knees in semi-reflexion, with his hands on his hip and he will be asked for an explosive jump, followed by a jump downwards falling the floor of the same way.~The technique of lateral jumps on cones will be carried out by means of unipodal jumps, achieving a distance of 50 cm between cones. The physiotherapist will stand in front of the athlete. The subject will be asked to perform a lateral unipodal explosive jump by flexing the hip and knee.
Study NCT03872076 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Elastic bands will be combined with isometric exercises in 3 sets of 10 repetitions each. The exercises they will perform are front squat. On the one hand, separating the legs at the height of the shoulders with hip and knee flexion, with the elastic band above the knees, maintaining the position 20 seconds.~In the following exercise, with the elastic band on the ankle, in unipodal support at the same time that the contralateral limb is free of support, the hip will be flexed at 45º with full knee extension, requesting the athlete to keep the tension 20 seconds, performing 3 sets of 10 repetitions.
Study NCT03247452 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One-day Low fiber diet
Description: One-day low fiber diet before colonoscopy
Study NCT03247452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three-day low fiber diet
Description: Three days low fiber diet before colonoscopy
Study NCT03247452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol plus ascorbic acid
Description: 2 liters of Polyethylene Glycol plus ascorbic acid will be administered to both groups
Study NCT03247452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol plus ascorbic acid
Description: 2 liters of Polyethylene Glycol plus ascorbic acid will be administered to both groups
Study NCT03478293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent inject surgery
Description: Micro-invasive glaucoma surgery (MIGS) to implant iStent inject
Study NCT01437306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine HCl
Description: 400 mcg (2 x 200 mcg tablets) administered orally as a single dose
Study NCT03598114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program Sustainability Action Planning Model and Training Curricula
Description: The Program Sustainability Action Planning Model and Training Curricula's conceptual model is driven by the theory of change and incorporates aspects of Kolb's experiential learning theory to produce a six step process: defining the program, assessing the program, developing an action plan, executing the action plan, evaluating sustainability, and reassessing and modifying. The study team will deliver in-person, hand-on workshops incorporating each of these aspects of the conceptual model. Following the workshop, intervention states will partake in technical assistance activities with the study team to track progress and troubleshooting challenges.
Study NCT03599375 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-targeted CART cells
Description: CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv.This is a second generation CRAT.
Study NCT00966875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2439821
Description: Subcutaneous
Study NCT04107454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active microablative fractional CO2 laser designed as SmartXide Touch C60, CO2 laser system for MonaLisa Touch, DEKA, Florence
Description: Active application of laser radiation on the vulvar skin. The laser setting is: Power 24 W, exposure time 400 microsec, density 6,4 %, pulse energy 23,2 mJ, fluenz 1,18J/cm2, emission mode DP, DOZ Dwell 400, DOT spacing 1000.
Study NCT04107454 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham microablative fractional CO2 laser designed as SmartXide Touch C60, CO2 laser system for MonaLisa Touch, DEKA, Florence
Description: Sham application of laser radiation on the vulvar skin. Laser setting is a sham dose:power 0, 5 W, exposure time 400 microsec, DOT spacing 1000
Study NCT01303549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Description: Anidulafungin once a day for 14 days: initial dose 200 mg/day IV administered in 180 minutes. Following doses 100 mg/day IV administered in 90 minutes.
Study NCT01303549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal amphotericin B
Description: Liposomal amphotericin B once a day for 14 days: 3 mg/kg/day. IV administration during 60 minutes.
Study NCT03446248 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Corometrics-146 device
Description: Fetal vibroacoustic stimulation with the Corometrics-146 fetal acoustic stimulator will be performed by placing the device on the maternal skin halfway between the pubic symphysis and the umbilicus and activating the device for 3 seconds.
Study NCT00966875 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous
Study NCT01206322 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intranasal insulin
Description: The acute effects of a single 40-IU dose of intranasal insulin
Study NCT01206322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Description: The acute effects of a single 40-IU dose of intranasal insulin
Study NCT01206322 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: The acute effects of intranasal sterile saline.
Study NCT01206322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The acute effects of intranasal sterile saline.
Study NCT04602234 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasonography
Description: Investigators performed lung ultrasonography on patients
Study NCT02930174 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive positive pressure ventilation
Description: Application of various levels of positive pressure
Study NCT06084975 — intervention group
Intervention type: PROCEDURE
Intervention: Splenic vessels preservation
Description: preservation the splenic vessels
Study NCT03706547 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19/BCMA CAR-T cells
Description: Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs
Study NCT03706547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2/d
Study NCT03706547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300mg/m2/d
Study NCT03886545 — intervention group
Intervention type: OTHER
Intervention: Assessment of physical and functional capacities
Description: Comparaison of physical and functional capacities between caregivers with work-related musculoskeletal disorders of the shoulder healthy subjects matched in age and gender;
Study NCT03446248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corometrics-146 device
Description: Fetal vibroacoustic stimulation with the Corometrics-146 fetal acoustic stimulator will be performed by placing the device on the maternal skin halfway between the pubic symphysis and the umbilicus and activating the device for 3 seconds.
Study NCT03446248 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile phone application
Description: Fetal vibroacoustic stimulation with the mobile phone will be performed by placing and iPhone on the maternal skin halfway between the pubic symphysis and umbilicus and using the application to activate for 3 seconds the phone's built in vibration along with a 2,000 Hz tone at a sound level of 74 decibels when measured at 1 meter.
Study NCT03446248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile phone application
Description: Fetal vibroacoustic stimulation with the mobile phone will be performed by placing and iPhone on the maternal skin halfway between the pubic symphysis and umbilicus and using the application to activate for 3 seconds the phone's built in vibration along with a 2,000 Hz tone at a sound level of 74 decibels when measured at 1 meter.
Study NCT00721747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Liposomal doxorubicine and Cyclophosphamide
Description: 4 cycles of Docetaxel 100mg/m2 iv followed by 4 cycles of Liposomal doxorubicine 60mg/m2/iv and Cyclophosphamide 600mg/m2/iv
Study NCT02138669 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intacs
Description: INTACS® prescription inserts are an ophthalmic medical device designed for the reduction or elimination of myopia and astigmatism in patients with keratoconus so that their functional vision may be restored and the need for a corneal transplant procedure can potentially be deferred.
Study NCT02722980 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention consists of capsules containing placebo.
Study NCT01636843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin), once weekly.
Study NCT01447966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Family based cognitive behavioral therapy with exposure and response prevention. Twice weekly for 45-60 minute visits.
Study NCT02722980 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: : Probiotic capsules
Description: The intervention consists of capsules containing probiotics.
Study NCT01425463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous (II) Glycine Sulphate Complex
Description: Oral dose of 567.7 mg Ferrous (II) Glycine Sulphate Complex three times a day (t.i.d) for 12 weeks (equivalent to 300 mg iron element per day for 12 weeks).~Administered orally with water.
Study NCT01425463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyferose
Description: Oral dose of 150 mg Polyferose Capsules twice daily (b.i.d) for 12 weeks (equivalent to 300 mg iron element per day for 12 weeks).~Administered orally with water.
Study NCT01425463 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Ferrous (II) Glycine Sulphate Complex
Description: Administered orally with water.
Study NCT01425463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to Polyferose
Description: Administered orally with water.
Study NCT00205920 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLVR Hydrogel
Description: 10 mL BLVR Hydrogel
Study NCT04395053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1459
Description: TR group:~The first period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h.~RT group:~The first period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h.
Study NCT00629967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha 2a and ribavirin
Description: pegylated interferon alpha 2a 180 mcg/week and ribavirin 1000-1200 mg/day for 48 weeks
Study NCT00629967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a and ribavirin
Description: Pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
Study NCT02852980 — intervention group
Intervention type: OTHER
Intervention: gestational diabetes women
Description: No intervention.
Study NCT02312700 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Interactive empowerment tool
Study NCT01788813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2245035
Description: Nasal spray solution, to be given intranasal, 80 ng/20 ng once weekly for 8 weeks
Study NCT01788813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal Spray Solution, to be given intranasal, once weekly for 8 weeks
Study NCT02312700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive empowerment tool
Study NCT03762564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15
Study NCT03762564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 on day 1, 8, 15
Study NCT03762564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 on day 1, 8, 15
Study NCT02907840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swisstom BB2
Description: Electrical impedance tomography lung monitoring uses a dedicated belt placed around patient's thorax to detect change in impedance due to change in aeration within the thorax
Study NCT04175990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone Pill
Description: started from day 1 of menses till trigger day
Study NCT02211911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl
Study NCT02211911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium picosulfate
Study NCT00945906 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FXIII Concentrate (Human) (FXIII)
Description: Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.~Subjects enrolled in this study who have not received at least 3 doses of FXIII Concentrate in a previous study of this product (i.e., NCT00640289, NCT00885742, or NCT00883090) will initially receive a dose of 40 U/kg by intravenous (IV) infusion.
Study NCT04874051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: The experimental treatment will be provided by means of the OAK system. This device consists of 1 cabinet with 2 independent balance boards, 2 monitors (one for the physiotherapist and one for the patient) and 3 wireless IMUs (one for the left lower limb, one for the right lower limb and one for the trunk). The 2 balance boards provide body weight transfer exercises, while the wireless motion sensors provide one leg stance exercises or trunk exercises in a virtual environment.
Study NCT04874051 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The Control Group will perform conventional balance exercises similar to the exercises provided with the OAK system.
Study NCT03954340 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iRemember Neurofeedback (NFB)
Description: Neurofeedback (NFB) is a treatment technique based on learning with operant conditioning, in which a feedback (or a reward) is given in proportion with the desired physiological activity in order to improve cognition and/or behavior. This research will focus on EEG-NF where electrical activity measured with EEG serves as the physiological activity to be influenced.~EEG-NFB has been successfully used as a clinical tool for over 40 years treating various disorders from Autism , ADHD , Epilepsy , OCD and depression Electroencephalography (EEG) equipment is used to measure the electrical activity representing the neuronal activity of different parts of the brain.~During the treatment, electrode(s) are placed in predetermined location. Audio and visual rewards are given when the activity is measured to be within the desired frequency range.
Study NCT03954340 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: iRemember Neurofeedback (NFB)
Description: Neurofeedback (NFB) is a treatment technique based on learning with operant conditioning, in which a feedback (or a reward) is given in proportion with the desired physiological activity in order to improve cognition and/or behavior. This research will focus on EEG-NF where electrical activity measured with EEG serves as the physiological activity to be influenced.~EEG-NFB has been successfully used as a clinical tool for over 40 years treating various disorders from Autism , ADHD , Epilepsy , OCD and depression Electroencephalography (EEG) equipment is used to measure the electrical activity representing the neuronal activity of different parts of the brain.~During the treatment, electrode(s) are placed in predetermined location. Audio and visual rewards are given when the activity is measured to be within the desired frequency range.
Study NCT01725659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Learning
Description: training of the hemiplegic upper limb with motor learning
Study NCT01725659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotics
Description: subjects perform training of hemiplegic arm using an upper extremity robot
Study NCT01725659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: surface FES
Description: subjects are provided with surface FES to the hemiplegic upper limb
Study NCT03000296 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Hematopoietic stem cell transplantation Lymphoablation followed by hematopoietic stem cell transplantation to rescue the immune system.
Study NCT04487132 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active physical education lessons and physical education plan
Description: Active physical education lessons and physical education plan Including importance of physical activity and health, and physical education plan; through lecture in classroom will be provided to the contyrolled group.
Study NCT04487132 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recess or lunch time activities
Description: group intervention will be provided ti the experimental group which includes Preparing the playground by offering adequate spaces and games.Developing games and teaching children to play in recess time at-least 10-15 minutes daily(i.e.sport games, traditional games) Placing a sheet in the classroom with some reminders about being active in recess time (i.e. using a poster board encouraging playing one of the selected games )
Study NCT02360462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.
Study NCT02360462 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after stimulation starts (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session
Study NCT01479738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Capitate bone grafting
Description: Capitate bone graft transfer for PIP joint reconstruction